Know Cancer

or
forgot password

Positron Emission Tomography Study in Patients With Non-Hodgkin Lymphoma


Phase 1
N/A
N/A
Not Enrolling
Both
Lymphoma

Thank you

Trial Information

Positron Emission Tomography Study in Patients With Non-Hodgkin Lymphoma


OBJECTIVES:

- To determine if a fluorine 18-fludeoxyglucose positron emission tomography scan,
performed as early as day 30 after high-dose chemotherapy and autologous stem cell
transplantation, may be useful in identifying patients with non-Hodgkin lymphoma who
may benefit from early interventions, including reduced intensity stem cell
transplantation or additional therapy, to preempt disease relapse and improve overall
survival.

OUTLINE: Conventional imaging, biopsy, and clinical examination findings are reviewed to
determine patient clinical outcome (e.g., complete remission, disease progression/relapse,
or death related to the primary disease).


Inclusion Criteria:



DISEASE CHARACTERISTICS:

- Diagnosis of non-Hodgkin lymphoma

- Has undergone high-dose chemotherapy followed by autologous stem cell transplantation
at Vanderbilt University between March 1997 and August 2005

- Has undergone fluorine 18-fludeoxyglucose PET within 70 days prior to and/or at
approximately 30 days and 100 days after high-dose chemotherapy and autologous
stem cell transplantation

Exclusion Criteria:

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Correlation of sensitivity, specificity, positive predictive value, and negative predictive value of fluorine 18-fludeoxyglucose positron emission tomography scan with with patients' clinical outcomes.

Outcome Time Frame:

from the date of stem cell transplant to date of clinical disease progression or to date of last follow-up

Safety Issue:

No

Principal Investigator

Adetola A. Kassim, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center

Authority:

United States: Federal Government

Study ID:

VICC BMT 0828

NCT ID:

NCT00712556

Start Date:

May 2008

Completion Date:

March 2009

Related Keywords:

  • Lymphoma
  • stage III adult Burkitt lymphoma
  • stage III adult diffuse large cell lymphoma
  • stage III adult diffuse mixed cell lymphoma
  • stage III adult diffuse small cleaved cell lymphoma
  • stage III adult immunoblastic large cell lymphoma
  • stage III adult lymphoblastic lymphoma
  • stage III grade 1 follicular lymphoma
  • stage III grade 2 follicular lymphoma
  • stage III grade 3 follicular lymphoma
  • stage III mantle cell lymphoma
  • stage III marginal zone lymphoma
  • stage III small lymphocytic lymphoma
  • stage IV adult Burkitt lymphoma
  • stage IV adult diffuse large cell lymphoma
  • stage IV adult diffuse mixed cell lymphoma
  • stage IV adult diffuse small cleaved cell lymphoma
  • stage IV adult immunoblastic large cell lymphoma
  • stage IV adult lymphoblastic lymphoma
  • stage IV grade 1 follicular lymphoma
  • stage IV grade 2 follicular lymphoma
  • stage IV grade 3 follicular lymphoma
  • stage IV mantle cell lymphoma
  • stage IV marginal zone lymphoma
  • stage IV small lymphocytic lymphoma
  • recurrent adult Burkitt lymphoma
  • recurrent adult diffuse large cell lymphoma
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent adult diffuse small cleaved cell lymphoma
  • recurrent adult immunoblastic large cell lymphoma
  • recurrent adult lymphoblastic lymphoma
  • recurrent childhood large cell lymphoma
  • recurrent childhood lymphoblastic lymphoma
  • recurrent childhood small noncleaved cell lymphoma
  • recurrent cutaneous T-cell non-Hodgkin lymphoma
  • recurrent grade 1 follicular lymphoma
  • recurrent grade 2 follicular lymphoma
  • recurrent grade 3 follicular lymphoma
  • recurrent mantle cell lymphoma
  • recurrent marginal zone lymphoma
  • recurrent small lymphocytic lymphoma
  • recurrent mycosis fungoides/Sezary syndrome
  • nodal marginal zone B-cell lymphoma
  • splenic marginal zone lymphoma
  • NC stage II adult immunoblastic large cell lymphoma
  • NC stage II adult lymphoblastic lymphoma
  • NC stage II grade 1 follicular lymphoma
  • NC stage II grade 2 follicular lymphoma
  • NC stage II grade 3 follicular lymphoma
  • NC stage II mantle cell lymphoma
  • NC stage II marginal zone lymphoma
  • NC stage II small lymphocytic lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Immunoblastic

Name

Location

Vanderbilt-Ingram Cancer CenterNashville, Tennessee  37232-6838
Vanderbilt-Ingram Cancer Center - Cool SpringsNashville, Tennessee  37064
Vanderbilt-Ingram Cancer Center at FranklinNashville, Tennessee  37064